You just read:

EMD Serono's Mavenclad Edges Past Novartis' Gilenya in the Recent Switch Segment of Canada's Multiple Sclerosis Market, Although Brand Familiarity Remains An Addressable Barrier

News provided by

Spherix Global Insights

May 28, 2019, 08:00 ET